AAP
HOWL icon

Arax Advisory Partners’s Werewolf Therapeutics HOWL Stock Holding History

Arax Advisory Partners’s Portfolio HOWL Stock Details HOWL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$32 Sell
12
-27
-69% -$18 ﹤0.01% 3691
2025
Q4 		$25 Sell
39
-29
-43% -$35 ﹤0.01% 4007
2025
Q3 		$133 Buy
+68
New +$93 ﹤0.01% 3480

Other funds holding HOWL

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
DF
DC Funds Mclean, Virginia $1.49M AUM 18.57% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Arax Advisory Partners's HOWL Position: Q1 2026 in Review

Arax Advisory Partners reduced its Werewolf Therapeutics (HOWL) stake by 69% in Q1 2026, selling an estimated $18 and leaving 12 shares worth $32. The position accounts for ﹤0.01% of the portfolio, ranked #3691.

Arax Advisory Partners first reported a position in HOWL in Q3 2025 and has held it in 3 quarters since. The position peaked at $133 in Q3 2025. 48 funds tracked by Wall St. Rank hold HOWL as of Q1 2026.

  • Arax Advisory Partners held 12 shares of Werewolf Therapeutics worth $32 as of Q1 2026.
  • Arax Advisory Partners sold 27 Werewolf Therapeutics shares in Q1 2026, an estimated $18.
  • Werewolf Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q1 2026, its #3691 holding.
  • Arax Advisory Partners first reported a position in Werewolf Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • Arax Advisory Partners's Werewolf Therapeutics position peaked at $133 in Q3 2025.
  • 48 funds tracked by Wall St. Rank held Werewolf Therapeutics as of Q1 2026.

Based on Arax Advisory Partners's 13F filing for Q1 2026, filed 13 May 2026.